Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 16/20 | 0.69 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.69 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.57 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.49 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | GRM5 | P41594 | 3/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20812661 | 0.85 | CRBN (0.70) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL25287772 | 0.84 | CRBN (0.80) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL29521506 | 0.84 | CRBN (0.80) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL31444095 | 0.83 | CRBN (0.75) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL31316584 | 0.81 | CRBN (1.00) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL23065968 | 0.81 | CRBN (0.73) | CRBNDDB1IKZF3GSPT1 | |
| SCHEMBL20811939 | 0.81 | CRBN (0.73) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL23355802 | 0.81 | CRBN (1.00) | CRBNDDB1IKZF3GSPT1BRD4 | |
| SCHEMBL9694471 | 0.81 | RAB9A (0.62) | CRBNDDB1GRM5 | |
| SCHEMBL20811941 | 0.81 | CRBN (0.69) | CRBNDDB1IKZF3GSPT1GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | claimed |
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| EP-1004580-B1 | Imides as inhibitors of TNF alpha | CELGENE CORP (US) | 2006-12-20 | — | — | EP | disclosed |
| EP-1477486-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2004-11-17 | — | — | EP | disclosed |
| US-6200987-B1 | ADMINISTERING AS TUMOR NECROSIS FACTOR INHIBITORS; CACHEXIA, ENDOTOXIN SHOCK; RETROVIRUS VIRICIDES | CELGENE CORPORATION | 2001-03-13 | — | — | US | disclosed |
| US-6075041-A | TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 2000-06-13 | — | — | US | disclosed |
| EP-1004572-A2 | Amines as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004581-A2 | Process for the preparation of thalidomide | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| EP-1004580-A2 | Imides as inhibitors of TNF alpha | CELGENE CORPORATION (US) | 2000-05-31 | — | — | EP | disclosed |
| US-5877200-A | Cyclic amides | CELGENE CORPORATION (US) | 1999-03-02 | — | — | US | disclosed |
| US-5698579-A | INHIBITOR OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| US-5605914-A | INHIBITORS OF TUMOR NECROSIS FACTOR | CELGENE CORPORATION (US) | 1997-02-25 | — | — | US | disclosed |
| EP-0706521-A1 | NOVEL IMIDES | CELGENE CORPORATION (US) | 1996-04-17 | — | — | EP | disclosed |
| US-5463063-A | Preparation of thalidomide; inhibitor of tumor necrosis factor | CELGENE CORPORATION (US) | 1995-10-31 | — | — | US | disclosed |
| WO-1995001348-A2 | IMIDES AS INHIBITORS OF TNP ALPHA | CELGENE CORPORATION (US) | 1995-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190076539-A1 | AMINE-LINKED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | GCGR, STUB1, GID4 | CRBN 23/4885DDB1 503/4885IKZF3 3499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.